Results 81 to 90 of about 3,972 (148)

TPM3–NTRK1 Fusion-Positive Thoracic Sarcoma: Integrated Diagnosis and Drug Repurposing

Indian Journal of Medical and Paediatric Oncology
Poorly differentiated or unclassifiable sarcomas may harbor targetable molecular alterations, and next-generation sequencing is valuable for an integrated diagnosis.
Kinjal Singh, Sameer Rastogi, Santhosh Kumar KN, Deepali Jain, Yamini Dharmashaktu   +4 more
doaj   +1 more source

Computer Assisted Drug Design of Larotrectinib for treatment of Cancer: A Combined Density Functional and Molecular Docking Study [PDF]

, 2019
This article talks about hypothesis behind the most critical strategies and later effective uses of halogen-coordinated Larotrectinib, ligand-based techniques utilize just ligand data for foreseeing action contingent upon its similitude/uniqueness to ...
Molla, Shamim
core   +1 more source

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

npj Precision Oncology
Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management ...
Vivek Subbiah, Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Mimi Hu, Luz E. Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu   +12 more
doaj   +1 more source

Entrectinib-Induced Pericarditis with Cardiac Tamponade in a Patient with Neurotrophic Tropomyosin Receptor Kinase 1 Fusion-Positive Breast Cancer

Case Reports in Oncology
Introduction: Entrectinib is a multikinase inhibitor used to treat neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced, or metastatic tumors. Cardiovascular events, such as congestive heart failure and myocarditis,
Aki Aoyama, Yutaro Yoshitomi, Akihiko Shimomura, Yukino Kawamura, Tomoko Taniyama, Atsumasa Kurozumi, Shuji Kubota, Yukio Hiroi, Chikako Shimizu   +8 more
doaj   +1 more source

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma

Frontiers in Oncology
Oncotherapy can shape intestinal microbiota, which, in turn, may influence therapy effectiveness. Furthermore, microbiome signatures during treatments can be leveraged for the development of personalised therapeutic protocols in cancer treatment based on
Luigia Turco, Rosa Della Monica, Rosa Della Monica, Pasqualina Giordano, Mariella Cuomo, Mariella Cuomo, Manuele Biazzo, Baptiste Mateu, Baptiste Mateu, Raimondo Di Liello, Bruno Daniele, Nicola Normanno, Antonella De Luca, Anna Maria Rachiglio, Carmela Chiaramonte, Francesca Maria Giugliano, Lorenzo Chiariotti, Lorenzo Chiariotti, Lorenzo Chiariotti, Giuseppe Catapano, Lorena Coretti, Lorena Coretti, Francesca Lembo, Francesca Lembo   +23 more
doaj   +1 more source

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: A short review on the current evidence

, 2019
The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal translocation involving the NTRK gene family occur across a wide range of cancers in both children ...
Ricciuti B., Crino L., Genova C., Libra M., Leonardi G. C.   +4 more
core   +1 more source

The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

Frontiers in Oncology
BackgroundOncogenic fusions of neurotrophic receptor tyrosine kinase NTRK1, NTRK2, or NTRK3 genes have been found in different types of solid tumors.
Philippe Metellus, Philippe Metellus, Clara Camilla, Clara Camilla, Emilie Bialecki, Nathalie Beaufils, Christine Vellutini, Eric Pellegrino, Pascale Tomasini, Pascale Tomasini, Manmeet S. Ahluwalia, Manmeet S. Ahluwalia, Alireza Mansouri, Isabelle Nanni, L’Houcine Ouafik, L’Houcine Ouafik   +15 more
doaj   +1 more source

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors

Acta Neuropathologica Communications
Background Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are found in 1% of gliomas across children and adults. TRK inhibitors are promising therapeutic agents for NTRK-fused gliomas because they are tissue agnostic and cross the blood ...
Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park   +10 more
doaj   +1 more source

Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study

Current Problems in Cancer: Case Reports
Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor ...
Martin Dietrich, Michel Velez
doaj   +1 more source

Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary. [PDF]

Future Oncol
Mascarenhas L, Ollis C, Singh Y, Menachery L, Burcoveanu DI, De La Cuesta E, van Tilburg CM, Laetsch TW.   +7 more
europepmc   +1 more source